Glucosyl Hesperidin Benefits in Primary Biliary Cholangitis: A Multicenter, Open-Label, Randomized Controlled Study.

What was studied

This trial tested glucosyl hesperidin (G-Hes) in primary biliary cholangitis (PBC). G-Hes activates an antioxidant pathway called NRF2/KEAP1. The trial was multicenter, open-label and randomized. It included 71 patients on maintenance therapy for PBC. They took G-Hes at 500 or 1,000 mg a day for 24 weeks. The study checked liver enzymes, blood fats and heme oxygenase 1.

What they found

The main outcome was gamma glutamyl transferase at week 24. In the high dose group only, it fell significantly, by 6.2. Alkaline phosphatase rose and bilirubin fell. Both reached significance only in the standard dose group. The authors think the alkaline phosphatase rise came from more bone metabolism. Transaminases did not change significantly in either group. In patients with abnormal baseline levels, gamma glutamyl transferase still fell by 6.4. This was only in the high-dose group. Alkaline phosphatase did not change significantly. Heme oxygenase 1 protein rose by 4.8 at week 24. That was not significant. No adverse events were related to G-Hes.

What it means for patients

The authors say adding G-Hes to existing treatment safely gave extra therapeutic effects in PBC.

Why it is not certain yet

This was an open-label trial. The gains were small and showed in single dose groups only. Alkaline phosphatase, a liver marker, rose in the standard dose group. The abstract gives no results on symptoms or long-term outcomes. Only 71 patients took part for 24 weeks.

Source

Glucosyl Hesperidin Benefits in Primary Biliary Cholangitis: A Multicenter, Open-Label, Randomized Controlled Study.

We restate facts from the source record in our own words. The original wording belongs to its publisher.